The Enfamil NEC lawsuit is entering a critical phase in 2026, with the first federal bellwether trial specifically targeting Mead Johnson — the maker of Enfamil — now postponed to early July 2026. Meanwhile, plaintiffs have already secured massive state court victories, including a $60 million verdict against Mead Johnson in Illinois and a staggering $495 million verdict against Abbott Laboratories in Missouri, signaling that juries are willing to hold formula manufacturers accountable for failing to warn parents about the risk of necrotizing enterocolitis in premature infants. As of March 2026, approximately 779 cases remain pending in the federal multidistrict litigation (MDL 3026) before Judge Rebecca Pallmeyer in the Northern District of Illinois, with an estimated 600 to 700 additional cases proceeding through state courts in Illinois, Missouri, and Pennsylvania.
The litigation landscape is genuinely mixed — Abbott has won summary judgment in three consecutive federal bellwether cases, while plaintiffs have dominated in state courts. A February 13, 2026 status conference confirmed that discovery remains on track, and parties have been ordered to submit an updated case management schedule by April 16, 2026. This article covers the latest trial results, upcoming bellwether dates, the scientific evidence driving the litigation, estimated settlement values, and what families affected by NEC should know going forward.
Table of Contents
- What Is the Current Status of the Enfamil NEC Lawsuit in 2026?
- State Court Verdicts Show Juries Siding With Families
- The Scientific Evidence Behind the NEC Formula Claims
- Estimated Settlement Values and What Families Should Expect
- Federal Bellwether Setbacks and What They Actually Mean
- Who Qualifies to File an Enfamil NEC Lawsuit
- What Comes Next in the Enfamil NEC Litigation
- Conclusion
- Frequently Asked Questions
What Is the Current Status of the Enfamil NEC Lawsuit in 2026?
The Enfamil NEC litigation sits at something of a crossroads. On the federal side, Judge Pallmeyer has granted summary judgment to abbott in three straight bellwether cases — the first dismissed on May 2, 2025, the second after a plaintiff’s causation expert was excluded in August 2025, and the third dismissed on October 24, 2025. These rulings were setbacks for the plaintiff side, but it is worth noting that all three involved Abbott’s similac products, not Enfamil. The first bellwether trial specifically involving Mead Johnson and Enfamil was originally scheduled for February 2026 but has been pushed back to early July 2026. That delay matters. A second wave of bellwether trials is already being prepared, with the first of those expected to begin in August 2026.
Industry observers and legal analysts are watching these upcoming trials closely because the state court results tell a very different story than the federal rulings. The $60 million verdict against Mead Johnson in March 2024 and the $495 million verdict against Abbott in July 2024 demonstrate that when these cases reach juries, plaintiffs can win — and win big. The disconnect between federal and state outcomes largely comes down to procedural differences, evidentiary rulings, and how individual judges have handled expert testimony challenges. One detail that underscores the continued momentum of this litigation: on May 14, 2025, Judge Pallmeyer denied Daubert motions to exclude two key plaintiff experts — Dr. Logan Spector, a pediatric epidemiologist, and Dr. Jennifer Sucre, a neonatologist. By preserving these expert witnesses, the court effectively affirmed that the scientific foundation of the plaintiffs’ case is strong enough to go before a jury, even as individual bellwether cases have stumbled on other grounds.
State Court Verdicts Show Juries Siding With Families
While the federal bellwether results have favored defendants, the state court track record paints a dramatically different picture. In March 2024, an Illinois jury returned a $60 million verdict against Mead Johnson after finding that a premature infant died from NEC after consuming Enfamil. That verdict was among the first to hold a formula manufacturer directly accountable for NEC-related harm, and it sent a clear message about how juries view the evidence when it reaches them without the procedural filters that have shaped federal outcomes. The July 2024 Missouri verdict was even more striking. A jury awarded $495 million against Abbott Laboratories — $95 million in compensatory damages and $400 million in punitive damages — after finding that a child developed NEC after being fed cow’s milk-based formula.
Punitive damages of that magnitude suggest the jury believed Abbott’s conduct went beyond mere negligence into willful disregard for infant safety. However, large punitive damage awards are frequently reduced on appeal, and defendants in mass tort cases routinely challenge these figures through post-trial motions. Families following this litigation should understand that headline verdict numbers and final payouts are often very different. There is also the matter of the October 2024 Missouri case, where a defense verdict was initially returned but then overturned on March 15, 2025 due to defense misconduct. That reversal is significant because it indicates the court found that the defense team’s behavior during trial was serious enough to undermine the integrity of the verdict — a relatively rare outcome that adds another layer of complexity to the litigation.
The Scientific Evidence Behind the NEC Formula Claims
The scientific case linking cow’s milk-based infant formula to NEC in premature infants draws on multiple study designs, and the numbers are difficult for defendants to dismiss. Randomized trials have shown a 67 percent increased NEC risk in infants fed formula compared to those receiving human milk. Cohort studies put that figure even higher, at a 226 percent increased risk. Case-control studies found 135 percent increased odds of NEC with formula feeding. And broadly, human milk has been shown to reduce NEC incidence by approximately 50 percent compared to formula in preterm infants. These are not fringe findings. They come from well-established research that has been peer-reviewed and repeatedly cited in clinical literature.
Dr. Logan Spector, who serves as a general causation expert for the plaintiffs, has built his testimony around this body of epidemiological evidence. Dr. Jennifer Sucre, a neonatologist, provides testimony on biological plausibility — essentially explaining the mechanisms by which cow’s milk proteins may damage the underdeveloped intestinal lining of premature infants and trigger the inflammatory cascade that leads to NEC. What makes this evidence particularly relevant to the litigation is the manufacturers’ awareness. Plaintiffs argue that Mead Johnson and Abbott knew about these risks for years and failed to provide adequate warnings to hospitals, neonatal intensive care units, and parents. The core legal theory is not that formula should never exist — it is that manufacturers had a duty to warn that their products carried specific, elevated risks for premature and very low birth weight infants, and that they aggressively marketed formula for use in NICUs despite the available science.
Estimated Settlement Values and What Families Should Expect
No global settlement has been reached in the MDL as of March 2026. Legal analysts currently estimate individual payouts in the range of $45,000 to $600,000 or more, depending on factors like the severity of the infant’s NEC diagnosis, whether surgery was required, long-term medical complications, and whether the child survived. Cases involving infant death or permanent intestinal damage requiring ongoing care would sit at the higher end of that range, while cases involving NEC that resolved with medical treatment but without surgery may fall toward the lower end. There is a meaningful tradeoff families need to weigh. Settling individually or as part of a global resolution means receiving compensation sooner but potentially accepting less than what a jury might award.
The state court verdicts — $60 million and $495 million — are obviously far above the estimated settlement range, but those are outlier results that carry appeal risk and do not reflect what most claimants would receive. A global settlement, if one materializes, would likely offer lower but more certain compensation across the entire class of plaintiffs. Industry observers have expressed hope that a global settlement could come together before the second wave of bellwether trials begins in August 2026, but that timeline is speculative. Families considering joining the litigation should also understand that MDL proceedings can move slowly. The MDL was established in April 2022, and nearly four years later, no resolution has been reached for the broader group of plaintiffs. Individual state court cases have moved faster in some jurisdictions, but they also carry greater financial risk for plaintiffs if the verdict goes the other way.
Federal Bellwether Setbacks and What They Actually Mean
The three consecutive federal bellwether losses for plaintiffs deserve careful context. Summary judgment in these cases means the judge determined that the evidence, viewed in the light most favorable to the plaintiffs, was insufficient to proceed to a jury trial. That is a higher bar than many people realize, and it does not necessarily mean the underlying science is weak. It often reflects specific evidentiary rulings, the particular facts of the individual case selected for bellwether treatment, or how the causation chain was presented. A critical limitation to understand is that bellwether cases are selected precisely because they test the boundaries of the litigation. They are not always representative of the strongest or weakest cases — they are chosen to help the court and the parties understand how key legal issues will play out.
The exclusion of a plaintiff’s causation expert in the second bellwether, for example, led directly to dismissal, but that ruling applied to that specific expert’s testimony in that specific case. It did not establish a blanket rule excluding causation testimony across the MDL, as evidenced by Judge Pallmeyer’s subsequent decision to deny Daubert challenges to Dr. Spector and Dr. Sucre. Plaintiffs should not panic over these federal results, but defendants should not be overconfident either. The upcoming July 2026 bellwether is the first to specifically involve Mead Johnson and Enfamil, and it will test whether the causation arguments that failed in the Abbott cases are stronger or weaker when applied to Enfamil products. Different products, different marketing materials, and different internal corporate knowledge could produce very different results.
Who Qualifies to File an Enfamil NEC Lawsuit
Eligibility generally requires that a premature infant — typically born before 37 weeks of gestation — was fed Enfamil or another cow’s milk-based formula in a hospital or NICU setting and subsequently developed necrotizing enterocolitis. Cases involving infants who required surgery, suffered bowel perforation, lost intestinal tissue, or died from NEC-related complications are considered the strongest claims.
Medical records documenting formula use and NEC diagnosis are essential, and families should be aware that statutes of limitations vary by state — in some jurisdictions, the clock starts when the injury is discovered rather than when it occurred, but this is not universal. Families who believe their child was harmed should consult with an attorney experienced in NEC formula litigation rather than relying on online intake forms from unfamiliar firms. The quality of legal representation matters significantly in mass tort cases, where individual case preparation can mean the difference between a strong settlement position and a case that is deprioritized.
What Comes Next in the Enfamil NEC Litigation
The next twelve months will likely determine the trajectory of the entire litigation. The July 2026 Enfamil-specific bellwether trial is the most important upcoming event. If plaintiffs secure a favorable verdict in federal court against Mead Johnson, it would dramatically shift settlement dynamics and could push the parties toward a global resolution.
If the defense prevails again, it could fragment the litigation further, with more plaintiffs opting to pursue claims in state courts where the results have been more favorable. The second wave of bellwether trials beginning in August 2026 will provide additional data points. The April 16, 2026 deadline for an updated case management schedule should also provide clarity on timelines and potential settlement discussions. With over 1,000 total cases nationwide and the scientific evidence consistently supporting a link between formula and NEC in preterm infants, this litigation is not going away — the only question is whether it resolves through mass settlement or continues case by case through the courts.
Conclusion
The Enfamil NEC lawsuit stands at an inflection point. State court juries have delivered massive verdicts — $60 million and $495 million — validating the claims of families whose premature infants developed necrotizing enterocolitis after being fed cow’s milk-based formula. Federal bellwether results have gone the other direction, with three consecutive defense wins on summary judgment, but the upcoming July 2026 trial against Mead Johnson specifically will test whether those federal outcomes extend to Enfamil or were tied to case-specific circumstances involving Abbott.
For families affected by NEC, the most important steps right now are preserving medical records, understanding the statute of limitations in your state, and connecting with experienced legal counsel. Estimated settlement values of $45,000 to $600,000 or more suggest meaningful compensation is possible, but the path to resolution remains uncertain. The scientific evidence — showing a 67 to 226 percent increased NEC risk with formula versus human milk — gives plaintiffs a strong foundation, and the preservation of key expert witnesses by the court ensures that foundation will be presented to future juries. Whether through global settlement or continued trials, this litigation will remain one of the most significant mass tort actions in 2026 and beyond.
Frequently Asked Questions
Has there been a settlement in the Enfamil NEC lawsuit?
No. As of March 2026, no global settlement has been reached in the MDL. Individual settlements may have occurred in specific cases, but no broad resolution has been announced. Industry observers hope a global settlement may come together before the second wave of bellwether trials in August 2026.
How much could an Enfamil NEC lawsuit be worth?
Legal analysts estimate individual payouts between $45,000 and $600,000 or more, depending on severity. Cases involving infant death, surgical intervention, or long-term complications are valued higher. State court jury verdicts have reached $60 million and $495 million, though those figures are subject to appeal and do not represent typical outcomes.
What is the next important date in the Enfamil NEC lawsuit?
The first federal bellwether trial specifically involving Mead Johnson (maker of Enfamil) is scheduled for early July 2026. Before that, parties must submit an updated case management schedule by April 16, 2026. A second wave of bellwether trials is expected to begin in August 2026.
What scientific evidence links Enfamil to NEC?
Multiple study types support the connection. Randomized trials show a 67 percent increased NEC risk with formula versus human milk, cohort studies show a 226 percent increase, and case-control studies show 135 percent increased odds. Human milk reduces NEC incidence by approximately 50 percent in preterm infants compared to formula.
Who qualifies to file an Enfamil NEC lawsuit?
Generally, families of premature infants (born before 37 weeks) who were fed Enfamil or cow’s milk-based formula and subsequently developed NEC may qualify. Strongest cases involve surgical NEC, bowel perforation, or infant death. Medical records documenting both formula use and NEC diagnosis are essential.
Why have plaintiffs lost federal bellwether trials but won in state court?
The outcomes reflect different procedural rules, evidentiary standards, and judicial approaches between federal and state courts. Federal bellwether losses involved summary judgment rulings and expert exclusions specific to those cases, while state court juries have heard the full evidence and returned large verdicts. The federal results do not bind state courts, and upcoming federal bellwethers may produce different outcomes.